The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

EJM van Bommel; MHA Muskiet; MJB van Baar; L Tonneijck; MM Smits; AL Emanuel; A Bozovic; AHJ Danser; Frank Geurts; Ewout Hoorn; DJ Touw; EL Larsen; HE Poulsen; MHH Kramer; M Nieuwdorp; JA Joles; DH van Raalte

doi:10.1016/j.kint.2019.09.013

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

EJM van Bommel
, MHA Muskiet
, MJB van Baar
, L Tonneijck
, MM Smits
, AL Emanuel
, A Bozovic
, AHJ Danser
, Frank Geurts
, Ewout Hoorn
, DJ Touw
, EL Larsen
, HE Poulsen
, MHH Kramer
, M Nieuwdorp
, JA Joles
, DH van Raalte

Internal Medicine

Research output: Contribution to journal › Article › Academic › peer-review

298 Citations (Scopus)

Original language	English
Pages (from-to)	202-212
Number of pages	11
Journal	Kidney International
Volume	97
Issue number	1
DOIs	https://doi.org/10.1016/j.kint.2019.09.013
Publication status	Published - 2020

Research programs

EMC MM-04-39-10
EMC OR-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.kint.2019.09.013

Cite this

van Bommel, EJM., Muskiet, MHA., van Baar, MJB., Tonneijck, L., Smits, MM., Emanuel, AL., Bozovic, A., Danser, AHJ., Geurts, F., Hoorn, E., Touw, DJ., Larsen, EL., Poulsen, HE., Kramer, MHH., Nieuwdorp, M., Joles, JA., & van Raalte, DH. (2020). The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney International, 97(1), 202-212. https://doi.org/10.1016/j.kint.2019.09.013

@article{9040db38725e4756ba309442f506d082,

title = "The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial",

author = "\{van Bommel\}, EJM and MHA Muskiet and \{van Baar\}, MJB and L Tonneijck and MM Smits and AL Emanuel and A Bozovic and AHJ Danser and Frank Geurts and Ewout Hoorn and DJ Touw and EL Larsen and HE Poulsen and MHH Kramer and M Nieuwdorp and JA Joles and \{van Raalte\}, DH",

year = "2020",

doi = "10.1016/j.kint.2019.09.013",

language = "English",

volume = "97",

pages = "202--212",

journal = "Kidney International",

issn = "0085-2538",

publisher = "Elsevier",

number = "1",

}

van Bommel, EJM, Muskiet, MHA, van Baar, MJB, Tonneijck, L, Smits, MM, Emanuel, AL, Bozovic, A, Danser, AHJ , Geurts, F , Hoorn, E, Touw, DJ, Larsen, EL, Poulsen, HE, Kramer, MHH, Nieuwdorp, M, Joles, JA & van Raalte, DH 2020, 'The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial', Kidney International, vol. 97, no. 1, pp. 202-212. https://doi.org/10.1016/j.kint.2019.09.013

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. / van Bommel, EJM; Muskiet, MHA; van Baar, MJB et al.
In: Kidney International, Vol. 97, No. 1, 2020, p. 202-212.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

AU - van Bommel, EJM

AU - Muskiet, MHA

AU - van Baar, MJB

AU - Tonneijck, L

AU - Smits, MM

AU - Emanuel, AL

AU - Bozovic, A

AU - Danser, AHJ

AU - Geurts, Frank

AU - Hoorn, Ewout

AU - Touw, DJ

AU - Larsen, EL

AU - Poulsen, HE

AU - Kramer, MHH

AU - Nieuwdorp, M

AU - Joles, JA

AU - van Raalte, DH

PY - 2020

Y1 - 2020

U2 - 10.1016/j.kint.2019.09.013

DO - 10.1016/j.kint.2019.09.013

M3 - Article

C2 - 31791665

SN - 0085-2538

VL - 97

SP - 202

EP - 212

JO - Kidney International

JF - Kidney International

IS - 1

ER -

van Bommel EJM, Muskiet MHA, van Baar MJB, Tonneijck L, Smits MM, Emanuel AL et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney International. 2020;97(1):202-212. doi: 10.1016/j.kint.2019.09.013